ASPEN-01: A Phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab, and paclitaxel in patients with 2nd line HER2-positive advanced gastric or gastroesophageal cancer
Conference Call
July 06, 2021
DISCLAIMER
This presentation contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology's beliefs and assumptions and on information currently available to it on the date of this presentation. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may
cause ALX Oncology's actual results, performance or achievements to be materially different from those expressed or implied by the
forward-looking statements. These and other risks are described more fully in ALX Oncology's filings with the Securities and Exchange Commission ("SEC"), including ALX Oncology's Annual Report on Form 10-K and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
This presentation concerns product candidates that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. These product candidates are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.
This presentation also contains estimates and other statistical data made by independent parties and by ALX Oncology relating to market size and growth and other industry data. This data involves a number of assumptions and limitations, and you are cautioned
not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of ALX Oncology's future
performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.
2
OVERVIEW
ALX Oncology (Nasdaq: ALXO) is a clinical-stageimmuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system
Lead product candidate ALX148 initiating multiple Phase 2 trials
CD47 blocker
- Designed for use in combination
- Tolerability profile enables higher dosing
- Higher dosing may enable greater efficacy
Clinical proof-of-principle in both hematologic and solid tumors
Initial focus on solid tumors, MDS, and AML
3
CD47: TUMOR ASSOCIATED ANTIGEN (TAA)- MYELOID CHECKPOINT DUALITY
TAA-Expression levels on cancer and normal cells | Checkpoint Mechanism: "do not eat me" |
SIRPαCD47
Macrophage
Don't eatme
Cancer cell
Eat me
Fc receptor
Anti-cancer drug
4
TARGETING CD47 AS TUMOR ASSOCIATED ANTIGEN
But also targets normal cells
Macrophage
Cancer cell | Red blood |
cell |
Fc receptor
CD47
Anti-CD47
SIRPα
Anti CD47 with active Fc
directly targets cancer cells
Anti-cancer drug
Dose limitations prevent full | |
blockade of CD47 and active | |
Fc competes with combo | |
drug | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
ALX Oncology Holdings Inc. published this content on 06 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 July 2021 12:03:03 UTC.